Next Article in Journal
Nanoplasmonic Paper-Based Platform for General Screening of Biomacromolecules
Next Article in Special Issue
Preparation of Carbon-Covered Phosphorus-Modified Alumina with Large Pore Size and Adsorption of Rhodamine B
Previous Article in Journal
Co2+ Substituted Spinel MgCuZn Ferrimagnetic Oxide: A Highly Versatile Electromagnetic Material via a Facile Molten Salt Route
Previous Article in Special Issue
Rapid Room-Temperature Preparation of Hierarchically Porous Metal–Organic Frameworks for Efficient Uranium Removal from Aqueous Solutions
Article

Combined Cutaneous Therapy Using Biocompatible Metal-Organic Frameworks

1
Advanced Porous Materials Unit (APMU), IMDEA Energy, Av. Ramón de la Sagra 3, 28935 Móstoles-Madrid, Spain
2
School of Chemistry, College of Science, University of Tehran, P.O. Box 14155-6455, Tehran 1417614411, Iran
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Nanomaterials 2020, 10(12), 2296; https://doi.org/10.3390/nano10122296
Received: 19 October 2020 / Revised: 19 November 2020 / Accepted: 20 November 2020 / Published: 25 November 2020
(This article belongs to the Special Issue Nanostructured Materials for Adsorption)
Combined therapies emerge as an interesting tool to overcome limitations of traditional pharmacological treatments (efficiency, side effects). Among other materials, metal-organic frameworks (MOFs) offer versatilities for the accommodation of multiple and complementary active pharmaceutical ingredients (APIs): accessible large porosity, availability of functionalization sites, and biocompatibility. Here, we propose topical patches based on water-stable and biosafe Fe carboxylate MOFs (MIL-100 and MIL-127), the biopolymer polyvinyl alcohol (PVA) and two co-encapsulated drugs used in skin disorders (azelaic acid (AzA) as antibiotic, and nicotinamide (Nic) as anti-inflammatory), in order to develop an advanced cutaneous combined therapy. Exceptional MOF drug contents were reached (total amount 77.4 and 48.1 wt.% for MIL-100 and MIL-127, respectively), while an almost complete release of both drugs was achieved after 24 h, adapted to cutaneous delivery. The prepared cutaneous PVA-MOF formulations are safe and maintain the high drug-loading capacity (total drug content of 38.8 and 24.2 wt.% for MIL-100 and MIL-127, respectively), while allowing a controlled delivery of their cargoes, permeating through the skin to the active target sites. The total amount of drug retained or diffused through the skin is within the range (Nic), or even better (AzA) than commercial formulations. The presented results make these drug combined formulations promising candidates for new cutaneous devices for skin treatment. View Full-Text
Keywords: metal-organic frameworks; combined therapy; azelaic acid; nicotinamide; cutaneous treatment metal-organic frameworks; combined therapy; azelaic acid; nicotinamide; cutaneous treatment
Show Figures

Graphical abstract

MDPI and ACS Style

Taherzade, S.D.; Rojas, S.; Soleimannejad, J.; Horcajada, P. Combined Cutaneous Therapy Using Biocompatible Metal-Organic Frameworks. Nanomaterials 2020, 10, 2296. https://doi.org/10.3390/nano10122296

AMA Style

Taherzade SD, Rojas S, Soleimannejad J, Horcajada P. Combined Cutaneous Therapy Using Biocompatible Metal-Organic Frameworks. Nanomaterials. 2020; 10(12):2296. https://doi.org/10.3390/nano10122296

Chicago/Turabian Style

Taherzade, Seyed D., Sara Rojas, Janet Soleimannejad, and Patricia Horcajada. 2020. "Combined Cutaneous Therapy Using Biocompatible Metal-Organic Frameworks" Nanomaterials 10, no. 12: 2296. https://doi.org/10.3390/nano10122296

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop